Subject: Update on Omaveloxolone Program, Phase 3 Pediatric Enrollment Completed Ahead of Schedule

Dear Friedreich Ataxia (FA) Community,

We are pleased to provide an update on the omaveloxolone program, reflecting our shared commitment to advancing care and research for people living with FA.

BRAVE Phase 3 Study in Children and Teens – Enrollment Milestone Reached

We are excited to announce that the BRAVE study, Biogen's global Phase 3 clinical trial evaluating the efficacy and safety of omaveloxolone in children aged 2 to 15 years with FA, has completed enrollment.

This milestone reflects the strong global reach of the study and was made possible by the incredible commitment of study sites in partnership with participants and families worldwide. More broadly, the FA community has been central to the successful recruitment and early completion, specifically the established infrastructure and patient engagement capabilities of the Friedreich's Ataxia Global Clinical Consortium (FA GCC) and the outreach and advocacy efforts of organizations such as the Friedreich's Ataxia Research Alliance (FARA). We are deeply grateful to the young individuals living with FA, their families, and the investigators who are giving their time and more to make this study possible. Their participation is essential to advancing research in areas of high unmet need such as FA.

The completion of enrollment in BRAVE represents a significant step forward in our ongoing commitment to advancing treatment options for children and adolescents living with FA.

About the BRAVE Study

The BRAVE study design has been shaped by insights from previous research, investigators, global medical experts, and the FA community. In Part 1, participants are randomly assigned to receive either omaveloxolone or placebo for 52 weeks with twice as many participants receiving omaveloxolone as those receiving placebo. The primary objective of the study is to evaluate changes in upright stability - a sensitive measure of disease progression in the pediatric population after 1 year of treatment. In Part 2, all participants will receive omaveloxolone for up to 104 weeks to assess long-term effects.

For more information, please contact Biogen at clinicaltrials@biogen.com. Updates will be posted on clinicaltrials.gov (NCT06953583) and Biogen Trial Link as the study progresses.

We are deeply appreciative to the entire FA community for achieving this milestone ahead of schedule and plan on providing updates as they become available.

Sincerely,

The Biogen Team